Literature DB >> 21899540

Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.

Elizabeth M Ryan1, Sean P Gorman, Ryan F Donnelly, Brendan F Gilmore.   

Abstract

OBJECTIVES: Bacteriophages are bacteria-specific viruses that infect and, in the case of obligately lytic phages, destroy their host bacteria. Phage therapy has been used therapeutically to combat bacterial infections since their discovery. This paper reviewed recent in-vivo phage therapy studies, with a distinct focus on the effect of delivery routes, phage concentration and timing of administration on the success of the therapy. KEY
FINDINGS: It was found that the most successful route of administration for the treatment of systemic infections was via the parenteral route. Oral delivery is mainly used to treat gastrointestinal infections. However, in some cases phages can also reach the systemic circulation. Local delivery (skin, ears, teeth) has proved extremely successful in the treatment of topical infections, as has the inhalation of phages for the treatment of lung infections. The ability of phages to prevent biofilm formation on medical devices has received much attention, mainly in the area of catheter coatings. This review also highlights areas in which phage therapy needs substantial development. Many papers were lacking in formulation details, with crude phage stocks being used in most cases. No phage stability data were included in any of the papers.
SUMMARY: The review concluded that although phage therapy is an excellent alternative for the treatment of bacterial infections, optimisation of formulations and long-term stability data is required before it can be widely used within a clinical setting.
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Year:  2011        PMID: 21899540     DOI: 10.1111/j.2042-7158.2011.01324.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  56 in total

Review 1.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

2.  Phage Therapy: Future Inquiries.

Authors:  Sijia Wu; Elisabeth Zachary; Keenan Wells; Catherine Loc-Carrillo
Journal:  Postdoc J       Date:  2013-06

3.  Polymicrobial Biofilm Studies: From Basic Science to Biofilm Control.

Authors:  Hubertine Me Willems; Zhenbo Xu; Brian M Peters
Journal:  Curr Oral Health Rep       Date:  2016-01-14

4.  Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

Authors:  Damien Maura; Matthieu Galtier; Chantal Le Bouguénec; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

5.  Effect of storage temperature on the stability of spray dried bacteriophage powders.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; An Nguyen; Thomas Gengenbach; Elizabeth A Carter; Nicholas B Carrigy; Hui Wang; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2018-02-24       Impact factor: 5.571

6.  The Presence of Two Receptor-Binding Proteins Contributes to the Wide Host Range of Staphylococcal Twort-Like Phages.

Authors:  Ippei Takeuchi; Keita Osada; Aa Haeruman Azam; Hiroaki Asakawa; Kazuhiko Miyanaga; Yasunori Tanji
Journal:  Appl Environ Microbiol       Date:  2016-09-16       Impact factor: 4.792

7.  Detection and quantification of Flavobacterium psychrophilum-specific bacteriophages in vivo in rainbow trout upon oral administration: implications for disease control in aquaculture.

Authors:  Rói Hammershaimb Christiansen; Inger Dalsgaard; Mathias Middelboe; Anne H Lauritsen; Lone Madsen
Journal:  Appl Environ Microbiol       Date:  2014-10-03       Impact factor: 4.792

8.  Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2018-09-14       Impact factor: 5.875

Review 9.  Novel approaches to the treatment of bacterial biofilm infections.

Authors:  Gareth Hughes; Mark A Webber
Journal:  Br J Pharmacol       Date:  2017-02-02       Impact factor: 8.739

10.  Cryomicroneedles for transdermal cell delivery.

Authors:  Hao Chang; Sharon W T Chew; Mengjia Zheng; Daniel Chin Shiuan Lio; Christian Wiraja; Yu Mei; Xiaoyu Ning; Mingyue Cui; Aung Than; Peng Shi; Dongan Wang; Kanyi Pu; Peng Chen; Haiyan Liu; Chenjie Xu
Journal:  Nat Biomed Eng       Date:  2021-05-03       Impact factor: 25.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.